GD2 ganglioside as a target for neuroblastoma immunotherapy

by cailynn on Aug 19th, 2025 07:45 AM

GD2 ganglioside as a target for neuroblastoma immunotherapy has gained attention due to its high expression on tumor cells and limited presence in normal tissues. This disialoganglioside is found on neuroectodermal tumors such as neuroblastoma and melanoma. GD2 ganglioside as a target for neuroblastoma immunotherapy enables the development of monoclonal antibodies and CAR-T therapies that selectively attack cancer cells while minimizing off-target effects.